Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

'Plasma first' approach for detecting epidermal growth factor receptor mutation in advanced non-small cell lung carcinoma.

Journal of cancer research and clinical oncology - 27 Jul 2024

Rathor Amber, Malik Prabhat Singh, Tanwar Pranay, Khurana Sachin, Baskarane Hemavathi, Pushpam Deepam, Nambirajan Aruna, Jain Deepali

Abstract excerpt

INTRODUCTION: The treatment approach for recently diagnosed advanced non-small cell lung cancer (NSCLC) with EGFR mutations primarily relies on confirming the tissue diagnosis as non-squamous NSCLC. This routine clinical practice of tissue diagnosis imposes several barriers and delays in turnaround time (TAT) for biomarker testing, significantly delaying the time to treatment. The objective of this study is to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers, Tumor

Share to Carcinoma, Non-Small-Cell Lung

Share to Cell-Free Nucleic Acids

Share to ErbB Receptors

Share to Liquid Biopsy

Share to Lung Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 39066920
DOI: 10.1007/s00432-024-05828-w
PMCID: PMC11283418

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

'Plasma first' approach for detecting epidermal growth factor receptor mutation in advanced non-small cell lung carcinoma.PMID 39066920Read ↗

Complementing Tissue Testing with Plasma mutation Profiling Improves Therapeutic Decision Making for Lung Cancer PatientsSemantic proximity Read ↗

Analysis of the effect of baseline detection and early clearance of ct-DNA, on survival outcomes among patients with advanced EGFR-mutant non-small cell lung cancer.Semantic proximity Read ↗

Clinical Utility of Liquid Biopsy (Cell-free DNA) Based EGFR Mutation Detection Post treatment Initiation as a Disease Monitoring Tool in Patients With Advanced EGFR-mutant NSCLC.Semantic proximity Read ↗

Upfront liquid next-generation sequencing in treatment-naïve advanced non-small cell lung cancer patients: A prospective randomised study in the Taiwanese health system.Semantic proximity Read ↗

Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer.Semantic proximity Read ↗

Retrospective Assessment of Complementary Liquid Biopsy on Tissue Single-Gene Testing for Tumor Genotyping in Advanced NSCLC.Semantic proximity Read ↗

A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung CancersSemantic proximity Read ↗

Guide to detecting epidermal growth factor receptor (EGFR) mutations in ctDNA of patients with advanced non-small-cell lung cancer.Semantic proximity Read ↗

Liquid Biopsy Versus Tissue Biopsy to Determine Front Line Therapy in Metastatic Non-Small Cell Lung Cancer (NSCLC).Semantic proximity Read ↗

Validation of liquid biopsy: plasma cell-free DNA testing in clinical management of advanced non-small cell lung cancerSemantic proximity Read ↗

Circulating tumor DNA: An alternative to tissue biopsy for detecting EGFR mutation in NSCLCSemantic proximity Read ↗

Large scale, prospective screening of EGFR mutations in the blood of advanced NSCLC patients to guide treatment decisions.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.